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Abstract 
Polycystic ovary syndrome (PCOS) is a complex metabolic and reproductive disorder 
that affects an extensive number of women of reproductive aged.  The purpose of this 
project was to critically appraise current evidence regarding the metabolic comorbidities 
associated and their impacts on women with PCOS with goals of identifying what 
evidence based assessment, evaluation, and treatment options are available to health care 
providers treating women with PCOS.  The results of this critical appraisal and consensus 
statements from The Endocrine Society and the American Society of Reproductive 
Medicine [ASRM] concluded that women with PCOS have an increased risk of 
developing type 2 diabetes, cardiovascular disease, and metabolic syndrome (Akbarzadeh 
et al., 2012; ASRM, 2012; Legro et al., 2013; Moran, Misso, Wild, & Norman, 2010; 
Tao, Shengxian, Zhao, Mao, & Liu, 2012; & Yilmaz, Isaoglu, Delibas, & Kadanali, 
2011).  An evidence based practice algorithm was developed from the results of this 
critical appraisal and consensus between both The Endocrine Society and ASRM on the 
diagnosis and treatment of PCOS.  The results of this critical appraisal and evidence-
based algorithm will assist Advanced Practice Nurses (ANPs) in continued health 
promotion and the prevention of the comorbidities associated with PCOS.     
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Polycystic Ovary Syndrome Metabolic Comorbidities: A Critical Appraisal of the 
Evidence with Practice Recommendations 
Polycystic ovary syndrome affects 5-10% of women of reproductive age (ASRM, 
2014).  Common PCOS signs and symptoms include anovulation or irregular menses, 
infertility, obesity, hirsutism, acne, and polycystic ovaries.  According to the American 
College of Obstetricians and Gynecologist ([ACOG], 2015) the cause of PCOS is 
multifactorial, including insulin resistance, increased levels of androgen hormones, and 
an irregular menstrual cycle.  Furthermore, insulin resistance associated with PCOS 
increases the risk of type 2 diabetes, cardiovascular disease, and metabolic syndrome 
(Moran et al., 2010).  
Polycystic ovary syndrome is a metabolic and reproductive disorder seen in 
women that persistently puzzles health care providers.  This disorder has a broad variety 
of phenotype presentation.  PCOS exhibits risk factors for cardio-metabolic disorders, 
women frequently presenting overweight or obese.  Affected women often have marked 
insulin resistance, independent of obesity (Diamanti-Kandarakis and Dunaif, 2012).  
Although insulin resistance is a contributing factor to the complications of PCOS, the 
current clinical diagnostic criteria do not address the endocrine pathology of the disorder.  
Insulin resistance is a central characteristic in the majority of affected women, driving 
both hyperandrogenism and clinical features (Stepto et al., 2013).  Androgen excess may 
correlate with metabolic risk and contribute at least in part to the adverse metabolic 
phenotype (O’Reilly et al., 2014).  
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Polycystic Ovary Syndrome Diagnostic Criteria 
In 1935, Stein and Leventhal published a case series of seven women with 
amenorrhea, hirsutism, and bilateral polycystic ovaries, a condition, which later became 
known as polycystic ovary syndrome (Roe & Dokras, 2011; Stein & Leventhal, 1935).   
Since the original description in 1935, the definition of PCOS has undergone several 
revisions (Roe & Dokras, 2011).  At the National Institute of Health (NIH) consensus 
conference held in 1990, PCOS was defined as; chronic anovulation with clinical and/or 
biochemical hyperandrogenism, with exclusion of other mimicking etiologies, such as 
thyroid or adrenal dysfunction (Appendix A) (Roe & Dokras, 2011; Zawadski & Dunaif, 
2001). 
Diagnostic Criteria Reformations 
Guidelines were re-examined by the Rotterdam Consensus Workshop in 2003 and 
revised to include polycystic ovaries by ultrasound (as defined by enlarged ovaries with 
at least 12 follicles) (Rotterdam, 2004).  At least two of the three clinical manifestations, 
anovulation, hyperandrogenism and/or polycystic ovaries, must be present to confirm the 
medical diagnosis of PCOS.  Some have argued that the expanded Rotterdam criteria can 
result in over diagnosis or misdiagnosis of PCOS; different phenotypes may not have 
similar risks of long-term metabolic morbidities (Roe & Dokras, 2011).  It may be 
perplexing to providers diagnosing women with PCOS who do not present with 
polycystic ovaries, causing a dubious meaning to the name of the diagnosis.  Most 
recently, the Androgen Excess Society (AES) developed diagnostic criteria for PCOS in 
2006 requiring inclusion of all three of the following: hyperandrogenism clinical and/or 
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biochemical, ovarian dysfunction (oligomenorrhea or anovulation and/or polycystic 
ovarian morphology), and exclusion of other androgen excess or related disorders 
(Appendix A).  The AES diagnostic criteria could cause concern again for misdiagnosis 
or underdiagnose of PCOS.  In 2008, the AES become the Androgen Excess and 
Polycystic Ovary Syndrome Society, and narrowed the diagnostic criteria further 
requiring the inclusion of the following, hyperandrogenism (hirsutism and/or 
hyperandrogenemia), and ovarian dysfunction (oligo-anovulation and/or polycystic 
ovaries), and exclusion of other androgen excess related disorders (Appendix A) (Azziz 
et al., 2009).  In December 2012, the NIH endorsed the acceptance of the Rotterdam 
criteria stating the Rotterdam criteria encompasses the broad spectrum of phenotypes 
representing PCOS (Trikudanathan, 2015).  The Endocrine Society also endorses the 
Rotterdam criteria for diagnosing PCOS (Legro et al., 2013).  Agreement amongst 
professional organizations that have focused on the perplexities of PCOS should provide 
confidence in utilizing the Rotterdam criteria for diagnosis of PCOS.  
Purpose and Question 
The purpose of this project is twofold:  to critically appraise current evidence 
regarding the metabolic comorbidities associated and their impacts on women with 
PCOS, and to identify evidence based assessment, evaluation, and treatment options 
available to health care providers treating women with PCOS.  The question this project 
aims to answer is; what is the relationship between PCOS and metabolic comorbidities 
and what evidence based assessment, evaluation, and treatment options are recommended 
for health care providers treating women with PCOS?  
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Ethical Considerations 
The Provost established the institutional review board (IRB) and Office of 
Academic Affairs to protect the interests of research subjects (University of Alaska 
Anchorage, [UAA], 2012).  The main role of the IRB is the review of all human subjects 
research conducted at UAA to ensure that the research fulfills the requirements of the 
federal regulations (UAA, 2012).  An IRB application for this critical appraisal research 
project was completed and submitted for review. (Appendix B).  The UAA compliance 
office determined that this critical appraisal research project did not meet the definition of 
human subjects research, as there would be no interaction or intervention with people.  
Study Design and Methods  
PICOT Format 
  The framework presented by Melnyk, Fineout-Overholt, and Williamson (2010), 
Seven Steps of Evidence Based Practice, guided the critical appraisal of the literature.  
The clinician poses a clinical question in step zero.  Step one, involves further 
development of the clinical questions using a format known as PICOT.  The PICOT helps 
to narrow and define the literature search.  Inquiries in this format take into account the 
patient population of interest (P), the intervention or area of interest (I), the comparison 
intervention or group (C), the outcome (O), and the time (T).  
The PICOT developed for this project includes the following: Population (P).  
The population of interest for this study is women with PCOS. Issue of Interest (I).  The 
issue of interest is metabolic comorbidities in women with a diagnosis of PCOS 
according to Rotterdam criteria. Comparison (C).  There will be no comparison in this 
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project. Outcome (O).  The outcomes of this project are to update health care providers of 
current evidence regarding metabolic comorbidities associated with PCOS and provide an 
evidence-based algorithm for assessment, evaluation, and treatment of women with 
PCOS and their comorbidities.  Timeframe (T).  Six months.  
Literature Search and Inclusion Criteria   
Step two, consists of a thorough literature search.  The search for evidence to 
inform clinical practice is tremendously streamlined when questions are asked in PICOT 
format (Melnyk et al., 2010).  Search terms were driven by the PICOT format developed 
in Step 1.  Databases utilized for searches included PubMed and the Cochrane Library.  
These databases were chosen based on recommendations from the UAA Consortium 
Librarian.  Keywords and search terms utilized in PubMed included: Polycystic Ovary 
Syndrome/diagnosis AND Insulin Resistance AND diagnostic criteria; Polycystic Ovary 
Syndrome/diagnosis AND Insulin Resistance; Polycystic Ovary Syndrome AND 
Metabolic Syndrome; Metabolic Syndrome AND Polycystic Ovary Syndrome.; 
Polycystic Ovary Syndrome/diagnosis"[Major]) AND "Metabolic Syndrome X"[Major]) 
AND "Insulin Resistance"[Major] AND ("last 5 years"[Publishing Date] AND 
Humans[Mesh] AND English[language]).   
Inclusion criteria focused on articles published between 2010-2015, the 
population of interest, articles written in the English language, and human subject 
research.  The initial search on PubMed produced 28 articles, 25 of which met the 
inclusion criteria.  Of the 25 publications, 23 articles were chosen for rapid critical 
appraisal for full text review.  Of the publications rapidly reviewed, 11 were excluded 
and 12 were chosen for full text review based on their significance to the project topic 
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and level of evidence presented in each study (Appendix C).  Studies included in the full 
text review were assessed using the standard level I-V hierarchy of evidence (Ebling 
Library, 2016).  Systematic reviews of randomized control trials, meta-analysis of 
randomized control trials, and experimental/randomized control trials or evidence based 
reviews of randomized control trials were assigned a level I.  Non-Randomized 
controlled trials, quasi-experimental, were assigned a level II.  Level III was assigned to 
well-designed control and cohort studies.  Systematic reviews of descriptive and 
qualitative studies were assigned a level IV, and level V was assigned to opinions of 
authorities and/or reports of expert committees.   
Studies selected for inclusion and full text review consisted of three systematic 
reviews and meta-analysis, seven cross-sectional studies, one case-control study, and one 
retrospective cohort study, levels I, II, and III evidence, respectively.   Additionally, 
sentinel works, such as the 2003 Rotterdam diagnostic criteria of PCOS, The Endocrine 
Society PCOS Clinical Practice Guideline, and the American Society of Reproductive 
Medicine Consensus on Women’s Health Aspects of PCOS were included due to their 
applicability to practice.  
Critical Appraisal.  Critically appraising the evidence is conducted in step three 
of the guiding framework.  Once articles were selected for review, they were rapidly 
appraised to determine which were most relevant, valid, reliable, and applicable to the 
clinical question (Appendix D).  Rapid critical appraisal uses three important questions to 
evaluate a study’s worth: 1) Are the results of the study valid; 2) What are the results and 
are they important; and 3) Will the results help me care for my patients? (Melnyk et al., 
2010).   
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An evaluation template was developed guided by Fineout-Overholt, Melnyk, 
Stillwell, and Williamson (2010) and was utilized to record data extracted from the 
studies utilized for this critical appraisal (Appendix E).  Studies were divided into 
categories according to the design of the study, study objectives, sample size, relevant 
findings, and presented in order of latest to oldest dates of publication.  
Synthesizing Evidence Findings and Algorithm Development.  The goal of 
step four, is integrating the evidence with clinical expertise and patient preferences and 
values.  For this critical appraisal, the focus of step four was to synthesize the evidence 
findings. Focus was directed on metabolic comorbidities associated with PCOS and 
recommendations for treatment from The Endocrine Society and ASRM.  Findings from 
this analysis were utilized to develop a treatment-based algorithm based upon the 
Rotterdam criteria, including recommendations of The Endocrine Society, and the 
American Society of Reproductive Medicine.  Evaluation methods for metabolic 
comorbidities in women with PCOS will also be included.  Step five of the guided 
framework for this critical appraisal consisted of the development of a treatment based 
algorithm (Appendix F).   
Dissemination.  Finally, step six, will be to disseminate the results of the critical 
appraisal.  Dissemination will include findings from the evidence and the developed 
treatment based algorithm in the form of a poster presentation and journal manuscript.  
The goal of the poster presentation will be to present at the annual Alaska Nurse 
Practitioner Association conference in 2016.  These goals for dissemination will provide 
an opportunity to share evidence based knowledge to ANPs and promote improved PCOS 
population outcomes. An abstract for poster presentation was submitted to the Alaska 
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Nurse Practitioner Association (Appendix G).  An additional abstract was submitted to 
Women’s Healthcare: A Clinical Journal for NPs for manuscript publication 
consideration.  This request for publication was declined due to the journal only 
accepting doctoral nursing research projects for publication (Appendix H). 
Literature Review 
Polycystic ovary syndrome is a common hormone disorder that affects 
approximately five million women of reproductive age in the United States (Johnson, 
Kaplan, Ouyang, & Rizza, 2012).  Several populations of women are at greater risk for 
PCOS.  These include reproductive-aged women with clinical evidence of 
hyperandrogenism, menstrual and/or ovulatory dysfunction, polycystic ovaries, and/or 
with insulin resistance or metabolic abnormalities (Moran et al., 2010).  In addition to its 
effects on reproductive health, it is now well recognized that PCOS is a metabolic 
disorder characterized by decreased insulin sensitivity which leads to an excess lifetime 
risk of type 2 diabetes and cardiovascular disease (Studen, Sever, & Pfeifer, 2013).  
Women with PCOS are often resistant to the biological effects of insulin and, 
consequently, may have higher levels of circulating insulin (Johnson et al., 2012).  
Women and particularly obese women with insulin resistance and polycystic ovary 
syndrome have an increased risk of developing gestational diabetes, type 2 diabetes, and 
cardiovascular disease later in life (Bhathena, 2011).  
PCOS Related Insulin Resistance 
  Polycystic ovary syndrome is recognized as an important metabolic and 
reproductive disorder conferring substantially increased risk for type 2 diabetes 
(Diamanti-Kandarakis & Dunaif, 2012).  Insulin resistance occurs in up to 20% of lean 
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women with PCOS, while the incidence is significantly higher (>40%) in obese women 
with the syndrome (Azziz et al., 2004; Balen, 2004; Bhathena, 2011; Dunaif, 1997; 
Dunaif, Segal, Futterweit, & Dobrjansky, 1989; Ehrmann, Barnes, Rosenfiled, & 
Cavaghan, 1999; Falcone, Finegood, Fautus, & Morris, 1990; Mather, Kwan, & 
Corenblum, 2000; Pasquali & Gambineri, 2006; RCOG, 2008; Tsilchorozidou, Overton, 
& Conway, 2004; & Wild, 2002).   
Insulin resistance results in a compensatory increase in insulin secretion by the 
islet cells of the pancreas to maintain normal glucose homeostasis (Azziz et al., 2009).  
Affected women have marked insulin resistance, independent of obesity (Diamanti-
Kandarakis & Dunaif, 2012).  As many as 70% of PCOS women are insulin resistant and 
10% have type 2 diabetes mellitus (Freeman, Pollack, & Rosenbloom, 2010; Azziz et al., 
2009).   Consequently, women with PCOS have a significantly higher rate of impaired 
glucose tolerance than those without the disorder (Dokras, 2013; Moran et al., 2010).  
The secondary hyperinsulinemia drives many of the phenotypic features of the disorder 
including the associated ovarian hyperandrogenism and acanthosis nigricans (Azziz et al., 
2009). 
Insulin Resistance PCOS Research   
A meta-analysis of 11 studies including 935 women with PCOS and 568 controls. 
Results from this meta-analysis showed an increased prevalence of impaired glucose 
tolerance (IGT) as defined by either the World Health Organization (WHO) or American 
Diabetes Association (ADA) definitions for IGT (Odds Ratio (OR) 2.48, 95% CI 1.62-
3.77) (Dokras, 2013; Moran et al., 2010).  The same authors performed a meta-analysis 
of 12 studies reporting that 12,102 women with PCOS compared to controls of 56,959 
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women had an increased prevalence for type 2 diabetes, with an OR of 4.43 (95% CI 
4.06-4.82) (Dokras, 2013; Moran et al., 2010).   
Moran et al. (2010) conducted a systematic review and meta-analysis, 2,192 
studies were reviewed and 35 were selected for final analysis.  This study focused on the 
prevalence of impaired glucose tolerance, type 2 diabetes, and metabolic syndrome in 
women with PCOS compared to women without PCOS.  Articles were included in the 
study based on the NIH and Rotterdam diagnostic criteria of PCOS.  The findings from 
this study concluded that women with PCOS had an increased prevalence of impaired 
glucose tolerance (OR 2.48, 95% CI 1.63, 3.77), diabetes type 2 (OR 4.43, 95% CI 4.06, 
4.82), and metabolic syndrome (OR 2.88, 95% CI 2.40, 3.45) compared to women 
without PCOS (Moran et al., 2010).  The prevalence of impaired glucose tolerance, 
diabetes type 2, and metabolic syndrome was found in both PCOS body mass index 
(BMI) matched and non-BMI matched studies.  No studies reported metabolic syndrome 
incidence (Moran et al., 2010). 
 Akbarzadeh et al. (2012) conducted a cross-sectional control study in women 
with PCOS diagnosed from the Rotterdam criteria investigating whether omentin and 
vaspin, secretory adipokines that are produced by the visceral adipose tissue, change in 
non-obese women with PCOS.  This study included 39 women diagnosed with PCOS 
using the Rotterdam diagnostic criteria, and a control group consisting of 39 women with 
normal pelvic sonographic reports having regular menstruation and no signs of infertility 
(Akbarzadeh et al., 2012).  Significant findings from this study reported insulin and 
fasting glucose levels demonstrating a noteworthy increase in insulin resistance in PCOS 
subjects (p = 0.007) (Akbarzadeh et al., 2012).  Akbarzadeh et al. concluded that if 
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hyperandrogenism and insulin resistance are early warning signs of increasing risk of 
PCOS, these patients are prime candidates for preventative medicine.  
A nonrandomized comparison trial conducted by Yilmaz et al. (2011) compared 
all phenotypes of PCOS for anthropometrical, hormonal, and metabolic difference 
according to Rotterdam criteria.  This study was conducted on 127 patients with PCOS 
and 44 control subjects without PCOS.  The four phenotypes of PCOS included patients 
with polycystic ovaries on ultrasound (PCO), oligo or anovulation (O) and biochemical 
and/or clinical hyperandrogenism (HA); 29/127 were HA and O, 24/127 were PCO and 
O, 18/127 were HA and PCO, and 42/127 represented the new phenotype PCO, O, HA, 
and PCO.  Glucose-insulin ratio which is important for insulin resistance was lower in 
phenotypes HA with O and PCO with HA and O than the other phenotypes and the 
control group (Yilmaz et al., 2011).  The highest values of insulin resistance were found 
to be in the phenotypes HA with O and PCO with HA and O phenotypes and the lowest 
values were in the HA with PCO, PCO with O phenotypes and the control group (Yilmaz 
et al., 2011).  Numbers of patients with insulin resistance according to phenotypes were 
as follows: PCO with HA and O (27/56; 48.21%), HA with O (12/29; 41.37%), HA with 
PCO (6/18; 33.33%), PCO with O (7/24; 29.16%) and the control group (13/44; 29.54%).  
Diagnosis of PCOS is independent to each individual and often binds women to 
continuous health care throughout their lifespan.  Accuracy of diagnosis is important and 
at times challenging with the features presented in PCOS.  
Additionally, Tao et al. (2012) conducted a cross-sectional study involving 137 
Chinese women with PCOS diagnosed from the Rotterdam criteria and 123 normal 
women as the control. Each participant underwent anthropometry, lipid profile, sex 
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hormone, high-sensitivity C reactive protein, oral glucose tolerance tests and insulin 
tolerance tests.  The aim of this study was to evaluate the levels of insulin sensitivity and 
beta cell function in Chinese women with PCOS. Tao et al. (2012) concluded that early 
impaired beta cell function was detected in both lean and obese Chinese women with 
PCOS; however more serious primary defect in insulin action was detected in lean 
Chinese women with PCOS compared to obese Chinese women with PCOS.  These 
findings imply early screening and intervention as therapeutic for Chinese women with 
PCOS (Tao et al., 2012).   
PCOS Related Androgen Excess 
  Hyperandrogenism is one of three diagnostic criteria measures presented in the 
Rotterdam criteria.  Hyperandrogenism is clinically manifested by hirsutism, acne, and 
androgenic alopecia.  Hirsutism is defined as increased terminal (coarse, pigmented) hair 
in a male pattern distribution around the upper lip, chin, shoulders, chest, periareolar 
areas, along the linea alba of the abdomen, inner aspects of the thighs, and midline lower 
back (Trikudanathan, 2015).  Women affected by androgen excess and/or PCOS often 
report unwanted hair growth, acne, and/or loss or thinning of hair.  
The pathophysiology of hyperandrogenism results from ovarian theca cells 
increase ovarian androgen production under the stimulatory activity of the elevated 
luteinizing hormone (LH) levels, and in many cases, elevated insulin levels (Abdel-
Rahman, 2015).  Hyperinsulinemia due to peripheral insulin resistance is often present in 
women with PCOS which promotes hyperandrogenemia through the binding of insulin to 
the insulin-like growth factor-1 (IGF-1) receptor.  Insulin mimics the action of IGF-1, 
which augments androgen production by the theca cell in response to LH, ultimately 
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stimulating an increase in circulating levels of free testosterone (Abdel-Rahman, 2015).   
The complexities of hyperinsulinemia in PCOS precipitate hyperandrogenemia and its 
presenting symptoms.   
Androgen Research 
A study conducted by O’Reilly et al. (2014) evaluated insulin resistance in 86 
PCOS patients fulfilling Rotterdam diagnostic consensus criteria.  Forty-three age and 
BMI matched controls underwent measurement of serum androgens by tandem mass 
spectrometry and an oral glucose tolerance test with homeostatic model assessment of 
insulin resistance and insulin sensitivity index calculation.  O’Reilly et al. (2014) 
analyzed urine androgen excretion by gas chromatography/mass spectrometry.  PCOS 
patients had higher levels of serum androgens and urinary androgen metabolites than 
controls (P < .001).  
 Wang, Kao, Huddleston, and Cedars (2011) conducted an additional study 
focusing on the effects of androgen excess.  This cross-sectional study consisted of 200 
women ages 18 to 44 years diagnosed with PCOS from the Rotterdam criteria.  The 
women where split into two groups, one with documented androgen excess the other 
documented without androgen excess. Wang et al. concluded that the women with 
androgen excess trended toward higher fasting glucose and lower HDL cholesterol than 
those without androgen excess.  A similar cross-sectional study conducted by Huang et 
al. (2015) examined 460 women diagnosed with PCOS from the Rotterdam criteria with a 
goal of identifying potential endocrine characteristics related to risk and severity of 
metabolic disturbances.  Huang et al. concluded that the highest risk for metabolic 
syndrome were the women with PCOS and those with higher free androgen index, the 
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fasting free androgen index correlated with more severe metabolic abnormal findings in 
this study.  Similarly, Yilmaz et al. (2011) also found higher free androgen index 
amongst women diagnosed with PCOS from the Rotterdam criteria than the women 
without PCOS in the control group. 
PCOS Associated Obesity 
Since the original description in 1935 by Stein and Leventhal, obesity is described 
as a common feature of PCOS (Sam, 2007).  Obesity has been linked to abnormal 
function of the hypothalamic-pituitary-ovarian (HPO) axis through multiple mechanisms 
that contribute to a development of PCOS (Legro, 2012).  A meta-analysis of 35 studies, 
including 15,129 women, demonstrated that women with PCOS had increased prevalence 
of being overweight or obese, with central obesity, compared with women without PCOS 
(Dokras, 2013; Lim, Davies, Norman, & Moran, 2012).  A similar meta-analysis of 30 
studies demonstrated that obese women with PCOS have decreased sex hormone binding 
globulin, increased testosterone, increased fasting glucose, increased fasting insulin, and 
abnormal lipid profile (Yildiz, 2013).  Obesity affects women with PCOS and is 
associated with insulin resistance.  The prevalence of insulin resistance is greater in obese 
than non-obese patients (Azziz et al., 2009).  Similarly, in the nonrandomized comparison 
study conducted by Yilmaz et al. (2011) the mean BMI was higher in phenotypes PCO 
with HA and O in addition to phenotype HA with PCO.  Waist to hip ratios were higher 
in women with PCO with HA and O, HA with PCO, and HA with O compared to PCO 
with O and controls.  
 Obesity affects a vast number of women in the United States.  The National 
Health and Nutritional Examination Survey from 2011-2012 documented data showing 
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36.6% of women ages 20 years and older in the United States were obese (Fryar, Carroll, 
& Ogden, 2014).  According to the WHO (2015), in 2014, more than 1.9 billion adults 
were overweight, over one third of those were obese.  The WHO (2015) defines obesity 
as a BMI > 30 kg/m2.  The association between obesity and alterations in female 
reproductive functions was recognized long ago (Rogers & Mitchell, 1952), and has been 
confirmed more recently.  The Practice Committee of the American Society of 
Reproductive Medicine [PCASRM] (2012) lists obesity as one of the most common 
causes of ovulatory dysfunction and anovulation infertility, although it may not affect all 
obese women. Additionally, research by Wilkes and Murdoch (2009) found that obese 
women have a higher prevalence of infertility, maternal morbidity, mortality, and fetal 
anomalies.  
PCOS Associated Risk for Dyslipidemia  
Women with PCOS have a high prevalence of several traditional risk factors for 
cardiovascular disease (Dokras, 2013).  These include controllable risk factors such as 
dyslipidemia, diabetes, hypertension, and obesity (Wild et al., 2010).  Increased risk of 
dyslipidemia including elevated low density lipoprotein (LDL), elevated triglycerides 
(TG) and low high density lipoprotein (HDL) has been shown in PCOS (Dokras, 2013). 
In a meta-analysis by Wilde et al. (2010), TG levels were significantly lower in control 
women, HDL levels were significantly higher in control women and LDL levels were 
significantly lower compared to women with PCOS.  Insulin resistance is a key factor in 
the pathophysiology of PCOS, thus dyslipidemia in women with PCOS may be consistent 
with those found in an insulin resistance state (Kim & Choi, 2013).  In a recent meta-
analysis, triglycerides and LDL cholesterol levels were 26 mg/dL and 12 mg/dL higher, 
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and HDL cholesterol concentration was 6 mg/dL lower in women with PCOS versus 
those of controls (Kim & Choi, 2013).  Wild (2012) concluded that on average, women 
with PCOS were found to have 26 mg/dl higher triglyceride [26.39 95%CI (17.24, 
35.54)], lower HDL cholesterol [6.41 95%CI (3.69, 9.14)], and higher non-HDL 
cholesterol levels [18.82 95% CI (15.53, 22.11)] than their non-PCOS counterparts.  A 
meta-analysis conducted by Wild (2012) confirmed in weight matched studies that 
women with PCOS have lower HDL cholesterol, higher non-HDL cholesterol, and higher 
LDL cholesterol concentrations in addition to higher triglycerides levels than age 
matched non PCOS women.  
Cochrane Systematic Reviews on Treatment Modalities for PCOS 
The Cochrane Library is a collection of six databases that contain different types of high-
quality, independent evidence to inform healthcare decision-making (Cochrane Library, 
2016).  Four Cochrane Library reviews that focused on treatment modalities of associated 
comorbidities of PCOS were examined for recommendations.  The reviews were selected 
based on date of publication between 2010 to 2015 and relevance to the study topic.  
Recommendations were found for treatment of PCOS with lifestyle modification 
including diet and exercise, insulin-sensitizing drugs, interventions for hirsutism, oral 
anti-diabetic agents, and statin therapy.  
 Moran, Hutchison, Norman, and Teede (2011) conducted a systematic review to 
assess the effectiveness of lifestyle treatment in improving reproductive, metabolic, 
anthropometric (weight and body composition), and quality of life factors in PCOS.  Six 
randomized control trials comparing lifestyle treatment (diet, exercise, behavioral or 
combined treatments) to minimal or no treatment in women with PCOS were included 
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with 164 participants (Moran et al., 2010).  Moran et al. concluded that lifestyle 
intervention improves body composition (weight P <0.00001, waist circumference  
(P .006), hyperandrogenism (hirsutism P 0.04), and insulin resistance (P 0.002) in women 
with PCOS.  There was no evidence of effect for lifestyle intervention on improving 
glucose tolerance or lipid profile and no literature assessing clinical reproductive 
outcomes, quality of life, and treatment satisfaction.  
  A systematic review conducted by Tang, Lord, Norman, Yasmin, and Balen 
(2011) examined the effectiveness of insulin-sensitizing drugs in improving reproductive 
outcomes and metabolic parameters for women with PCOS.  Tang et al. (2011) selected 
44 randomized controlled trials of insulin sensitizing drugs compared with either placebo, 
no treatment, or an ovulation induction agent for women with PCOS, menstrual 
disturbance, and subfertility for inclusion.  Thirty-eight of the studies used metformin and 
involved 3,495 women.  Tang et al. (2011) concluded that there was no evidence that 
metformin improved live birth rates, whether it was used alone or in combination with 
clomiphene; however, clinical pregnancy rates were improved with metformin versus 
placebo and for metformin and clomiphene versus clomiphene alone.  In studies that 
compared metformin and clomiphene alone, there was evidence of an improved live birth 
rate and clinical pregnancy rate in the group of obese women who took clomiphene (Tang 
et al., 2011).  The role of metformin in improving reproductive outcomes in women with 
PCOS appears to be limited (Tang et al., 2011).  
 An additional systematic review conducted by Raval, Hunter, Stuckey, & Hart 
(2011) conducted a systematic review to assess the efficacy and safety of statin therapy 
for women with PCOS who are not actively trying to conceive.  Of the randomized 
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control trials comparing a statin versus placebo or statin combination with another drug 
versus another drug alone in women with PCOS, 244 women with PCOS fulfilled the 
study inclusion criteria.  Raval et al. (2011) concluded that statins improved lipid profiles 
and reduced testosterone levels in women with PCOS (P < 0.00001).  In women with 
PCOS, statins are effective in reducing serum androgen levels and decreasing LDL 
cholesterol, but did not prove to be effective in reducing fasting insulin or insulin 
resistance (Raval et al., 2011).  
Literature Review Conclusions 
There is a clear consensus throughout the literature that women with PCOS have a 
significantly higher rate of impaired glucose tolerance, type 2 diabetes, dyslipidemias, 
and metabolic syndrome (Akbarzadeh et al., 2012; Moran et al., 2010; Tao et al., 2012; & 
Yilmaz et al., 2011).  Hyperandrogenism is a main feature of PCOS; evidence suggests 
that insulin resistance or insulin action play critical roles in its pathophysiology (Huang et 
al., 2015; O’Reilly et al., 2014; Wang et al., 2011; & Yilmaz et al., 2011).  Dyslipidemia 
in women with PCOS has been linked to insulin resistance.  The presence of 
dyslipidemia, insulin resistance, and obesity in women with PCOS are intricately related 
as a preventable cause of morbidity.   
The current diagnostic criteria for PCOS does not include insulin resistance, 
obesity, or other cardio-metabolic disorders such as dyslipidemia.  The results from this 
literature review supports that women with PCOS having a higher prevalence of insulin 
resistance then women without PCOS (Akbarzadeh et al., 2012; Moran et al., 2010; Tao 
et al., 2012; & Yilmaz et al., 2011).  While impaired insulin resistance and obesity are not 
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included in the current diagnostic criteria for PCOS, the clinical impact associated with 
these metabolic comorbidities should not be ignored. 
Recommendations from Professional Organizations 
Recommendations and guidelines from two main professional organizations that 
focus on the diagnosis and treatment complexities of PCOS were appraised for this 
project, The Endocrine Society, and the American Society of Reproductive Medicine.  
The Endocrine Society 
 The Endocrine Society is a prestigious professional organization that has been 
representing professionals in all aspects of endocrinology for 100 years.  Founded in 
1916, The Endocrine Society is the world’s oldest, largest and most active organization 
devoted to research on hormones and the clinical practice of endocrinology (Lohr & 
Gingery, 2013).  The Endocrine Society issued a Clinical Practice Guideline (CPG) for 
the diagnosis and treatment of PCOS, the most common hormone disorder in women of 
reproductive age and a leading cause of infertility (Lohr & Gingery, 2013).  The CPG is 
designed to assist health care providers with the complexities of PCOS diagnosis and 
treatment.  
Endocrine Society PCOS Clinical Practice Guideline.  The Endocrine Society 
suggests using the Rotterdam criteria for diagnosing PCOS, which include two of the 
following criteria: androgen excess, ovulatory dysfunction, or polycystic ovaries (Legro 
et al., 2013).  In regards to the cardio-metabolic abnormalities associated with PCOS the 
guidelines developed by The Endocrine Society advise screening women for impaired 
glucose tolerance and type 2 diabetes with the use of an oral glucose tolerance test and/or 
a hemoglobin A1c if the individual is unable to complete or refuses an oral glucose 
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tolerance test.  Rescreening is suggested every three to five years, or more frequently if 
clinical factors such as central adiposity, substantial weight gain, and/or symptoms of 
diabetes develop (Legro et al., 2013).  This guideline recommends providers screen for 
cardiovascular risk factors associated with PCOS such as obesity, smoking, hypertension, 
and dyslipidemia.  
 Hormonal contraceptives (i.e. oral contraceptives, patch, or vaginal ring) are 
recommended as first-line management for the menstrual abnormalities and 
hirsutism/acne of PCOS (Legro et al., 2013).  Metformin is second-line therapy for 
menstrual cycle irregularities in women who cannot take or tolerate hormonal 
contraceptives (Legro et al., 2013).  Life style modifications including weight loss is 
addressed in the guidelines and should be encouraged.  Weight loss for obese and 
overweight women with PCOS beginning with restricted caloric intake is recommended 
as beneficial for both reproductive and metabolic dysfunctions.  Metformin is 
recommended for women with type 2 diabetes and those with impaired glucose tolerance 
who fail lifestyle modification (Legro et al., 2013).  The Endocrine Society recommends 
against the use of metformin as first-line treatment for androgen excess associated 
symptoms of hirsutism and/or acne.  
American Society of Reproductive Medicine 
The American Society of Reproductive Medicine is a multidisciplinary 
organization dedicated to the advancement of the science and practice of reproductive 
medicine (ASRM Board of Directors, 2014).  The Society accomplishes its mission 
through the pursuit of excellence in education and research and through advocacy on 
behalf of patients, physicians, and affiliated health care providers.  Two widely cited 
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consensus statements developed by the European Society of Human Reproduction and 
Embryology [ESHRE]/ASRM focused on PCOS diagnosis (2004) and infertility 
management (2008) (ASRM, 2012).  The most resent PCOS consensus report 
summarizes current knowledge and identifies gaps regarding various women’s health 
aspects of PCOS addressing both the diagnosis and treatment of PCOS (ASRM, 2012).  
Both The Endocrine Society and American Society of Reproductive Medicine address the 
diagnosis and treatment of PCOS. 
 American Society of Reproductive Medicine Consensus on PCOS.  Relevant 
topics addressed PCOS in adolescence, hirsutism and acne, contraception, menstrual 
cycle abnormalities, quality of life, ethnicity, pregnancy complications, long-term 
metabolic and cardiovascular health, and cancer risk (ASRM, 2012).  Similarly, to the 
Endocrine Society, the ESHRE/ASRM consensus also recommends utilization of the 
Rotterdam diagnostic criteria for the diagnosis of PCOS (ASRM, 2012).  Agreement on 
the Rotterdam criteria between both organizations should provide confidence in utilizing 
the Rotterdam criteria for the diagnosis of PCOS.  
 Consensus was found between ESHRE and ASRM workshop that obesity is 
increasing and has an important bearing on the phenotype of PCOS.  Obesity (by 
amplifying insulin resistance) is an exacerbating factor in the development of impaired 
glucose tolerance and diabetes type 2 in PCOS.  ASRM recommends two main treatment 
modalities for PCOS; lifestyle management and metformin. Lifestyle management with 
caloric restricted diet and exercise on obesity result in weight loss and improvement in 
surrogate markers of metabolic disease/syndrome (ASRM, 2012).  Diet and exercise are 
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first choice for improving fertility and prevention of diabetes.  Metformin is 
recommended for impaired glucose tolerance and diabetes type 2.   
Metabolic disorders associated with PCOS are major predictors of prediabetes, 
diabetes, and metabolic syndrome in reproductive-age women.  Not all PCOS phenotypes 
have similar metabolic risk; the combination of hyperandrogenemia and oligomenorrhea 
signifies the most at-risk (ASRM, 2012).  ASRM, conclude that insulin resistance is a 
prominent feature of PCOS making PCOS a major risk factor for developing impaired 
glucose intolerance and diabetes type 2.  Recommendations from the ESHRE and ASRM 
consensus directed at the care of diabetes type 2 in PCOS include screening for impaired 
glucose intolerance and diabetes type 2 by oral glucose tolerance testing.  Screening for 
impaired glucose tolerance was recommended in the following conditions: 
hyperandrogenism with anovulation, acanthosis nigricans, obesity (BMI >30 kg/m2, or 
BMI >25 in Asian populations), and in women with a family history of diabetes type 2 or 
gestational diabetes (ASRM, 2012).  
 The metabolic dysfunctions associated with PCOS increase the risk for 
cardiovascular disease. The ESHRE/ASRM consensus concluded that PCOS at any age is 
characterized by greater odds for elevated cardiovascular risk markers, elevated markers 
occurring without obesity and are magnified with obesity.  Dyslipidemia, impaired 
glucose tolerance, and type 2 diabetes, classic risk indicators of atherosclerosis and 
cardiovascular disease, are more prevalent in women with PCOS, even when weight 
matched with normal control women (ASRM, 2012).  ESHRE and ASRM consensus 
recommendations including a cardiovascular risk assessment at any age for psychological 
stress, blood pressure, glucose, lipid profile (cholesterol, triglycerides, HDL, LDL, and 
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non-HDL cholesterol), waist circumference, physical activity, nutrition, and tobacco use 
(ASRM, 2012).   
In addition to cardio-metabolic risk factors, menstrual cycle irregularities are also 
an important feature of PCOS and should be addressed.  It is unclear to what extent the 
severity of the menstrual disturbance is associated with the severity of the PCOS 
phenotype (ASRM, 2012).  Menstrual cycle abnormalities can be controlled in woman 
with PCOS and is usually achieved by using hormonal contraceptive management.  
Overall, the benefits of hormonal contraceptives outweigh the risks in most patients with 
PCOS, and are recommended as first line treatment of irregular menstrual cycles in 
women with PCOS not trying to conceive (ASRM, 2012). Oral contraceptives can 
address many of the goals of reproductive-aged women with PCOS; ameliorate 
hyperandrogenic skin manifestations and regulate menstrual cycles. Norethindrone, 
norgestrel, and levonorgestrel are known to have androgenic activity, whereas 
desogestrel, norgestimate, and gestodene are less androgenic. The pills containing 
progestin with antiandrogenic activity, rather than second and third generation oral 
contraceptives containing progestins with varying androgenic activity, appear to be an 
appropriate alternative in the treatment of PCOS (ASRM, 2012).  
Synthesis of Professional Organization Recommendations 
 Consensus was found between the ESHRE and ASRM and The Endocrine 
Society on the treatment and management of PCOS and associated comorbid risk factors.  
Both the Endocrine Society and the ESHRE and ASRM endorse the use of the Rotterdam 
criteria as the diagnostic criteria of choice for PCOS.  In addition, both organizations 
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recommend life style modifications including restricted caloric intake and exercise for 
weight loss management in obese and overweight women with PCOS.   
Women with PCOS should be screened for impaired glucose tolerance utilizing 
an oral glucose tolerance test in addition to screening for other cardio-metabolic risk 
factors including tobacco use, hypertension, obesity, and dyslipidemia (ASRM, 2012; 
Legro et al., 2013).  First-line treatment for diabetes type 2 in women with PCOS should 
include metformin (ASRM, 2012; Legro et al., 2013; Tang et al., 2011).  In women with 
impaired glucose tolerance who fails life style modification should be treated with 
metformin as second line therapy.  Recommendations by both organizations for first-line 
treatment of menstrual cycle irregularities in women with PCOS not trying to conceive 
includes the use of hormonal contraception, which may also be beneficial in the treatment 
of hirsutism and acne (ASRM, 2012; Legro et al., 2013).  The clear similarities amongst 
both of these professional organizations will assist health care providers in accurate 
diagnosis and treatment of women with PCOS.  
Results  
The results of the critical appraisal and consensus statements from The Endocrine 
Society and the American Society of Reproductive Medicine conclude that women with 
PCOS have an increased risk of developing type 2 diabetes, cardiovascular disease, and 
metabolic syndrome (Akbarzadeh et al., 2012; ASRM, 2012; Legro et al., 2013; Moran et 
al., 2010; Tao et al., 2012; & Yilmaz et al., 2011).  The high prevalence of insulin 
resistance amongst women with PCOS has been documented in several studies, 
indicating insulin resistance plays a significant role in PCOS (Akbarzadeh et al., 2012; 
Moran et al., 2010; Tao et al., 2012; & Yilmaz et al., 2011).  The current diagnostic 
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criteria do not address metabolic comorbidities as one of the criteria in diagnosing PCOS, 
yet they remain a critical aspect of comprehensive treatment for this complex syndrome.  
Given the impact metabolic comorbidities have on women with PCOS, the 
Endocrine Society and the American Society of Reproductive Medicine agree that 
screening should be performed for metabolic comorbidities in women with PCOS (Legro 
et al., 2013; ASRM, 2012).  Both professional organizations concluded that metabolic 
screening for impaired glucose intolerance and diabetes type 2 should be performed by an 
oral glucose tolerance test.  Equally, each also recommends lifestyle modification 
through diet and exercise as the first-line treatment for weight loss and diabetes 
prevention.  Additionally, both recommend the use of metformin in women with PCOS 
who have diabetes type 2 and those with impaired glucose tolerance who have failed 
lifestyle modifications. A consensus between the two organizations was also found 
utilizing hormonal contraceptives for menstrual cycle irregularities, hirsutism, and acne is 
indicated. 
Theoretical Framework 
In 1975 Nola J. Pender developed a conceptual model for preventative health 
behavior (Pender, 1982).  Pender’s health-promotion model notes that each person has 
unique personal characteristics and experiences that affect subsequent actions (Gonzalo, 
2011).  The set variables for behavior specific knowledge and affect have important 
motivational significance; these variables can be modified through nursing actions 
(Gonzalo, 2011).  Assumptions of the health promotion model reflect both nursing and 
behavioral science perspectives.  Pender emphasizes the active role the patient embodies 
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by shaping and maintaining health behaviors and in modifying the environment and 
context for health behaviors (Masters, 2015).   
The health promotion model is useful in practice when the focus of nursing care 
includes promoting behaviors to enhance health (Masters, 2015).  The role of the nurse in 
Pender’s health-promotion model revolves around raising consciousness related to 
health-promotion behaviors, promoting self-efficacy, enhancing the benefits of changes, 
controlling the environment to support behavior changes, and managing the barriers to 
change (Pender, Murdaugh, & Parsons, 2006).  There are three major categories to 
consider in Pender’s health promotion model: (1) individual characteristics and 
experiences, (2) behavior-specific cognitions and affect, and (3) behavioral outcome 
(Masters, 2015).  This analysis will focus on behavioral outcome.  Health promoting 
behavior, which is ultimately directed toward attaining positive health outcomes, is the 
product of the health promotion model (Masters, 2015).  In the context of this analysis, 
behavioral outcome is defined as identifying metabolic comorbidities in women with 
PCOS, ultimately promoting health and disease prevention.   
Applying the Evidence to Clinical Practice 
The development of the evidence-based treatment algorithm was efficiently 
constructed from the synthesized results determined from the through literature review 
conducted for this project.  Results concluded from the literature review were weighted 
along side the recommendations for diagnosis and treatment of PCOS presented by both 
The Endocrine Society and ASRM.   Similar and supportive results presented in the 
literature were highlighted along side those presented in each of the professional 
organization recommendations.  Areas of consensus throughout the literature and 
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professional recommendations were outlined in a rough draft algorithm, narrowed to 
provide the best evidence-based recommendations for evaluation, assessment, diagnosis, 
and treatment of PCOS in the form of a treatment based algorithm.      
Impact on Advanced Nursing Practice 
 Advanced nurse practitioners (ANPs) are primary care providers who are at the 
forefront of health promotion and disease prevention.  ANPs have a comprehensive 
approach to practice and are able to recognize the different features of PCOS.  With the 
evidence provided from this critical appraisal, ANPs will be able to identify high-risk 
patients with PCOS and screen them appropriately to prevent additional morbidity and 
mortality.  An evidence-based algorithm will assist ANPs in health promotion and the 
prevention of the comorbidities associated with PCOS.    
Conclusion 
The aim of this project was two fold: 1) to evaluate the evidence about the 
associated metabolic comorbidities in women with PCOS and 2) educate providers with 
current evidence based critical appraisal findings.  The development of a treatment based 
algorithm for assessment, evaluation, and treatment of women with PCOS and the 
metabolic comorbidities was developed based upon synthesis of this critical appraisal. 
Treatment and diagnostic recommendations from The Endocrine Society and the ASRM 
were developed (Appendix F).   The clinical practice algorithm will assist health care 
providers in the treatment of women with PCOS.  Utilizing current evidence-based 
recommendations ultimately increases health promotion, disease prevention, and 
improved health outcomes.   
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NIH Criteria (1990) 
All three of the following: 
• Clinical or biochemical evidence of hyperandrogenism 
• Oligomenorrhea and/or anovulation 
• Exclusion of other disorders 
Rotterdam Criteria (2003) 
At least two of the following: 
• Oligomenorrhea and/or anovulation 
• Clinical and/or biochemical signs of hyperandrogenism 
• Polycystic ovaries 
PCOS can be diagnosed only after the exclusion of related disorders (e.g., severe insulin 
resistance, androgen-secreting neoplasms, Cushing’s syndrome, hyperprolactinemia and 
thyroid abnormalities) 
Androgen Excess Society Criteria (2006) 
All three of the following: 
• Chemical or biochemical hyperandrogenism  
• Ovarian dysfunction (oligomenorrhea or anovulation or polycystic ovarian 
morphology) 
• Exclusion of other androgen excess related disorders 
PCOS is predominantly a disorder of androgen excess.  
 
Androgen Excess and PCOS Society Criteria (2008) 
All three of the following: 
• Hyperandrogenism: hirsutism and/or hyperandrogenemia 
• Ovarian Dysfunction: oligo-anovulation and/or polycystic ovaries 
• Exclusion of other androgen excess or related disorders 
 
  
Adapted from the NIH, Rotterdam, AES, & AE-PCOS Society diagnostic criteria of PCOS by Azziz, 
Carmina, Dewailly, Diamanti-Kandarakis, Escobar-Morreale, Futterweit, et al., 2009; Rotterdam 
ESHRE/ASRM, 2003; Roe et al., 2011, Zawadski & Dunaif, 2001. 
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Appendix C 
 
Data Search Process 
 
 
 
 
 
  
 
Initial search findings 
N=28 
Publications meeting 
inclusion criteria (date, 
human subjects, English 
language) 
N=25 Publications chosen for 
rapid critical appraisal 
for full text review 
N=23 
Publications excluded 
after critical appraisal 
review 
N=11
Publication chosen for full 
text critical ap raisal 
N=12 
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Appendix D 
Rapid Critical Appraisal (RCA) for Full Text Review 
Author (year)  Are the 
results 
valid?  
What are the results and 
are they important? 
Will the 
results help 
me care for 
my 
patients?
Baptiste, C.G., 
Battista, M.C., 
Trottier, A., & 
Baillargeon, J.P. 
(2010) 
Review  Yes. The main feature of 
PCOS is hyperandrogenism 
and evidence suggest that 
insulin resistance or insulin 
action plays in its 
pathophysiology. Further study 
needed to confirm.   
Yes.  
Moran, L.J., Misso, 
M.L., Wild, A., & 
Norman, R.J. (2010) 
Systematic 
Review 
Women with PCOS had an 
elevated prevalence of IGT, 
DM2, and metabolic syndrome 
in both BMI matched and non-
BMI matched studies. 
Yes. 
Phelan, N. et al., 
(2010) 
Case-control 
study 
Yes. Women with PCOS have 
potentially important 
differences in lipid profile with 
greater LDL levels and 
increased rates of more 
atherogenic non-LDL pattern.  
Yes. 
Excluded, 
diagnosis not 
based on 
Rotterdam, 
NIH.  
Yilmaz, M., Isaoglu, 
U., Delibas, I.B., & 
Kadanali, S. (2010).  
Non-
randomized 
comparison 
Decrease risk of metabolic 
comorbidities in women with 
only polycystic ovaries and 
anovulation. Yes. 
Yes. 
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Bhathena, R.K. 
(2011) 
Review  Yes. Women with PCOS have 
reproductive disturbances and 
insulin resistance, are at risk 
for development of cardio-
metabolic abnormalities 
similar to those that lead to 
metabolic syndrome.  
Yes.  
 
Manneras-Holm et 
al., (2011) 
 
Non-
randomized 
comparison 
 
Yes. Increase in adipose tissue 
was found to be associated 
with insulin resistance in 
PCOS. 
 
Yes.  
Excluded, 
diagnosis 
criteria not 
identified.  
Wild, R.A., Rizzo, 
M., Clifton, S., & 
Carmina, E. (2011) 
Systematic 
review/meta-
analysis 
Yes. Dyslipidemia is common 
in PCOS. 
Yes.  
Akbarzadeh, S. et al., 
(2012) 
Cross-sectional 
case control 
study 
Yes. Results show that PCOS 
is not a determinant of 
decreased omentin and vaspin 
plasma levels and those high 
androgen level and insulin 
resistances are warning sings 
of PCOS. 
Yes.  
Bonny, A.E. et al., 
(2012) 
Cross-sectional, 
anonymous, 
internet survey 
No. Heterogeneity between 
providers initial diagnosing 
and management of PCOS 
among members of NASPAG 
was consistent.  
No. 
Excluded 
 
Lim, S.S., Norman, 
R.J., Davies, M.J., & 
Moran, L.J. (2012) 
Systematic 
review/meta-
analysis 
Yes. Obesity significantly 
worsened all metabolic & 
reproductive outcomes 
measured except for hirsutism 
when compared to normal 
weight women with PCOS.  
Yes. 
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Rahmanpour, H., 
Jamal, L., 
Mousavinasab, S.N., 
Esmailzadeh, A., & 
Azarkhish (2012) 
Randomized Yes. Obesity and insulin 
resistance are important risk 
factors for metabolic syndrome 
in PCOS. 
Yes.  
Excluded, 
diagnosis 
criteria not 
based on 
Rotterdam 
criteria, NIH. 
Tao, T., Li, S., Shao, 
A., Mao, X., & Lui, 
W. (2012).  
Cross-sectional Early impaired beta cell 
function was detected in 
lean/obese women with PCOS. 
Yes. 
Yes. 
Yildiz, B.O., Bozdag, 
G., Yapici, Z., 
Esinler, I., & Yarali, 
H. (2012) 
Cross-sectional 
study 
Higher rate of dx of PCOS 
with Rotterdam criteria 
compared to others. Yes. 
Yes. 
Roe, A.H., 
Prochaska, E., Smith, 
M., Sammel, M., & 
Dokras. (2013) 
Retrospective 
chart review 
Adolescents diagnosed with 
PCOS based on the AE-PCOS 
criteria are at significantly 
increased risk of >1 metabolic 
abnormality. Yes. 
Yes. 
Excluded, 
diagnostic criteria 
not based on 
Rotterdam criteria, 
NIH. 
 
Yidiz, B. (2013) 
 
Meta-analysis 
 
Yes. Obese women with PCOS 
have multiple comorbidities 
associated with obesity. 
 
Yes.  
Excluded, 
diagnosis not 
based on 
Rotterdam 
criteria, NIH. 
Mani, H. et al., 
(2013) 
20-year 
retrospective 
cohort study 
Yes. Showed a high incidence 
of diabetes and cardiovascular 
events in women with PCOS. 
Yes.  
Aydogdu, A. et al., 
(2013) 
Non-
randomized 
comparison 
study 
Yes. Increase in subscapular & 
suprailiac skinfold thickness 
are increased in women with 
PCOS with significant relation 
to impaired insulin resistance.  
No.  
Excluded. 
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Kim, J.J., & Choi, 
Y.M. (2013).  
Review  Yes. Although the prevalence 
of obesity in Korean women 
with PCOS is low, even young 
and non-obese Korean women 
with PCOS have substantially 
increased prevalence of 
dyslipidemia.  
Yes.  
Kim, J.J. et al., 
(2013) 
Case-control 
study  
Yes. Non-obese women with 
PCOS may have no significant 
quantitative or qualitative 
changes in LDL-C profiles 
Yes.  
Dokras, A. (2013)  Review  Yes. Women with PCOS have 
a higher risk for cardiovascular 
disease.  
Yes.  
Livadas, S., Kollias, 
A., Panidis, D., & 
Kandarakis, E.D. 
(2014) 
Cross-sectional 
study 
Yes. In PCOS age was 
negatively and BMI was 
positively associated with 
insulin resistance.  
Yes 
O’Reilly et al. (2014)  Cross-sectional 
study 
Yes. PCOS patients had higher 
levels of serum androgens and 
urinary androgen metabolites 
than controls. 
Yes 
Huang, C.C., et al. 
(2015) 
Cross-sectional 
study 
Major predictor of metabolic 
abnormalities was free 
androgen index and luteinizing 
hormone. Yes.  
Yes. 
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Appendix E 
 
Evidence Evaluation Table Full Test Reviewed Articles 
Author 
(year) 
Study Objectives Design Sample size 
Rotterdam 
criteria 
Relevant 
Findings 
Huang, C.C., 
et al. (2015) 
What are the 
potential endocrine 
characteristics 
related to risk and 
severity of 
metabolic 
disturbances in 
women with PCOS? 
Cross-sectional 
study 
460 
participants 
Rotterdam 
criteria 
High rates of 
metabolic 
syndrome and free 
androgen index in 
participants with 
PCOS.  
Livadas, S., 
Kollias, A., 
Panidis, D., & 
Kandarakis, 
E.D. (2014) 
To evaluate the 
changes in insulin 
resistance and its 
associations with 
clinical, 
biochemical, 
hormonal, and 
ultrasound findings 
in a large cohort of 
women with PCOS 
and controls, as they 
are aging.  
Cross-sectional 
study 
1345 women 
with PCOS 
Rotterdam 
criteria 302 
controls of 
Caucasian 
origin and 
Greek 
ethnicity 
comprised 
the control 
group 
Aging increases 
insulin resistance 
in obese but not in 
lean and over 
weight women 
with PCOS. 
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O’Reilly et al. 
(2014) 
Androgen excess 
may correlate with 
metabolic risk and 
PCOS consensus 
criteria define 
androgen excess on 
the basis of serum 
testosterone.  
Cross-sectional 
study 
86 women 
with PCOS 
Rotterdam 
criteria 43 
age and BMI 
controls. 
Measurements of 
serum testosterone 
and 
androstenedione 
levels represents a 
useful tool for 
predicting 
metabolic risk in 
PCOS women; 
high 
androstenedione 
levels are a 
sensitive indicator 
of PCOS-related 
androgen excess. 
Kim, J.J. et 
al., (2013) 
Is a preponderance 
of small dense LDL 
cholesterol observed 
in non-obese women 
with PCOS? 
Case-control 
study 
64 PCOS 
patients 
Rotterdam 
criteria and 
64 age-BMI 
matched 
controls 
Findings suggest 
that non-obese 
women with 
PCOS may have 
no significant 
quantitative or 
qualitative 
changes in LDL 
cholesterol.  
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Mani, H. et 
al., (2013) 
The incidence and 
prevalence of 
cardiovascular 
events in a cohort of 
women with PCOS. 
(20-year) 
retrospective 
cohort study 
2301 women 
Rotterdam 
criteria 
Data showed high 
incidence and age-
group specific 
prevalence of type 
2 diabetes, 
myocardial 
infarction, and 
angina in the 
women with 
PCOS. Age, 
history of 
hypertension, and 
smoking had 
significant 
correlations with 
cardiovascular 
outcomes in the 
PCOS patients.   
Akbarzadeh, 
S. et al., 
(2012) 
Investigate whether 
omentin and vaspin 
levels change in 
non-obese PCOS 
subjects.  
Cross-sectional 
case control 
study 
39 women 
with PCOS 
Rotterdam 
criteria 
39 women 
for control 
group with 
normal pelvic 
sonographic 
reports 
having 
regular 
menses and 
no signs of 
infertility  
PCOS is not a 
determinant of 
decreased omentin 
and vaspin. High 
androgen level and 
insulin resistances 
are warning signs 
of PCOS.  
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Lim, S.S., 
Norman, R.J., 
Davies, M.J., 
& Moran, L.J. 
(2012) 
Assess the effects of 
overweight, obesity 
and central obesity 
on the reproductive, 
metabolic, and 
psychological 
features of PCOS. 
Systematic 
review/meta-
analysis 
30 eligible 
studies 
Being overweight 
adversely affects 
many aspects of 
PCOS while being 
obese further 
worsens these 
outcomes.  
Tao, T., Li, 
S., Shao, A., 
Mao, X., & 
Lui, W. 
(2012). 
Clarify the 
pathogenic features 
by evaluating the 
levels of insulin 
sensitivity and beta 
cell function in 
women with PCOS.  
Cross-sectional 137 Chinese 
women with 
PCOS 
Rotterdam 
criteria & 
127 normal 
women  
Early impaired 
beta cell function 
was detected in 
both lean and 
obese women with 
PCOS; more 
serious primary 
defect in insulin 
action was 
detected in lean 
women compared 
to obese women.  
Yildiz, B.O., 
Bozdag, G., 
Yapici, Z., 
Esinler, I., & 
Yarali, H. 
(2012) 
What is the 
prevalence, 
phenotype, and 
metabolic features 
of PCOS in the same 
population 
according to three 
different diagnostic 
criteria? 
Cross-sectional 
study 
392 women 
with PCOS 
Rotterdam 
criteria 
Higher rates of 
women were 
diagnosed with 
PCOS under 
Rotterdam criteria 
and a higher rate 
of metabolic 
syndrome was 
diagnosed under 
the NIH criteria.  
Wild, R.A., 
Rizzo, M., 
Clifton, S., & 
Carmina, E. 
(2011) 
To quantify the 
magnitude and 
pattern of LDL 
cholesterol and HDL 
cholesterol levels in 
women with PCOS 
versus control 
women. 
Systematic 
review/meta-
analysis 
2710 women 
with PCOS 
Rotterdam 
criteria 
and/or NIH 
criteria 
 
1657 non-
PCOS 
controls  
Dyslipidemia is 
common in PCOS. 
Women with 
PCOS have higher 
LDL cholesterol 
and non HDL 
cholesterol 
regardless of BMI. 
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Moran, L.J., 
Misso, M.L., 
Wild, R.A., & 
Norman, R.J. 
(2010).  
PCOS is a common 
condition in 
reproductive aged 
women associated 
with IGT, DM2, and 
metabolic syndrome. 
Systematic 
Review 
2,192 studies 
reviewed, 35 
selected for 
final analysis 
Women with 
PCOS had an 
elevated 
prevalence of IGT, 
DM2, and 
metabolic 
syndrome in both 
BMI and non BMI 
matched studies.  
Yilmaz, M., 
Isaoglu, U., 
Delibas, I.B., 
& Kadanali, 
S. (2010). 
To compare all 
phenotypes of PCOS 
for 
anthropometrical, 
hormonal, and 
metabolic 
differences 
according to 
Rotterdam criteria.  
Cross-sectional 
study 
127 women 
with PCOS 
Rotterdam 
criteria  
44 non-
PCOS 
controls 
Women with just 
polycystic ovaries 
and anovulation 
(PCO+O) were at 
decreased risk of 
development of 
metabolic 
syndrome and 
insulin resistances 
than other 
phenotypes.  
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Appendix G 
 
 
Thank you for your interest in presenting a poster at the Alaska Nurse Practitioner 
Association’s Annual Conference. Poster presentations are valued by the conference 
attendees and showcase research by fellow nurse practitioners. Please submit the follow 
for review by the selection committee.  
The date for the poster presentation is September 22, 2016 at 4-5pm. The poster 
presentations need to be attended for the entire hour by the presenter. Please submit the 
following information below. If you are selected to present, you will be contacted by a 
member of the selection committee. Additional information will be requested at that 
time.   
Please email submissions to: presidentelectANPA@gmail.com 
Name: Rhianne Christopherson (907) 223-9202; rhiannechristopherson@gmail.com 
School: University of Alaska Anchorage 
Program: MSN-Family Nurse Practitioner 
Title of Poster: PCOS Evidence-Based Algorithm 
Abstract (Less than 150 words) 
 Abstract 
Polycystic ovary syndrome (PCOS) is a complex metabolic and reproductive disorder that affects 
an extensive number of women of reproductive aged.  The purpose of this project was to 
critically appraise current evidence regarding the metabolic comorbidities associated and their 
impacts on women with PCOS with goals of identifying what evidence based assessment, 
evaluation, and treatment options are available to health care providers treating women with 
PCOS.  The results of this critical appraisal and consensus statements from The Endocrine 
Society and the American Society of Reproductive Medicine [ASRM] concluded that women 
with PCOS have an increased risk of developing type 2 diabetes, cardiovascular disease, and 
metabolic syndrome (Akbarzadeh et al., 2012; ASRM, 2012; Legro et al., 2013; Moran, Misso, 
Wild, & Norman, 2010; Tao, Shengxian, Zhao, Mao, & Liu, 2012; & Yilmaz, Isaoglu, Delibas, 
& Kadanali, 2011).  An evidence based practice algorithm was developed from the results of this 
critical appraisal and consensus between both The Endocrine Society and ASRM on the 
diagnosis and treatment of PCOS.  The results of this critical appraisal and evidence-based 
algorithm will assist Advanced Practice Nurses (ANPs) in continued health promotion and the 
prevention of the comorbidities associated with PCOS.    
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Appendix H 
 
Hi Rhianne, 
  
Thanks for sending us your letter of inquiry.  
  
With respect to publishing research projects in Women's Healthcare: A Clinical 
Journal for NPs, we consider only those completed for a DNP degree, not a 
master's degree. Also, even if we were to consider a master's degree project, 
we've published an article on PCOS in the recent past and have more on this 
topic in the pipeline. 
  
If you have a doctoral research project for us to review in a few years, please do 
send it our way! 
  
Sincerely, 
Dory 
  
Dory Greene, Managing Editor 
Women's Healthcare: A Clinical Journal for NPs 
Work: 908-903-0230 
Fax: 908-903-0231 
Mobile: 908-347-4592 
